Pulmonary hemodynamic changes in chronic thromboembolic pulmonary hypertension may be monitored via the 6-minute walk test.
Bosentan may benefit a subset of patients with idiopathic pulmonary fibrosis-associated pulmonary hypertension.
A clinical trial is underway to assess the safety and efficacy of dabigatran in intermediate-risk pulmonary embolism after completing 72 hours of heparin therapy.
The REVEAL risk score gives significant predictive value for long-term survival and changes in mortality risk in patients with PAH.
A fully implantable programmable intravascular delivery system using treprostinil was found to be highly stable in patients with PAH.
Pulmonary hypertension may be more important than age in predicting heart transplant outcomes.
A study evaluated whether changes in estimated glomerular filtration rate were predictive of mortality in patients with pulmonary arterial hypertension.
Prospective validation research is needed before these clinical predictors of pediatric PE can become guidelines.
A systematic review evaluated whether catheter-directed thrombolysis improved outcomes in patients with intermediate-risk pulmonary emboli.
The use of veno-arterial extracorporeal membrane oxygenation as bridge therapy for massive pulmonary embolism may allow clinicians to better triage patients to appropriate destination therapy.